Zhongyianke Biotech

Zhongyianke Biotech is a China-based private vaccine biotechnology company focused on the development, manufacturing, and commercialization of human prophylactic vaccines. The company has marketed an influenza vaccine and has disclosed additional vaccine programs spanning tetravalent influenza, tetravalent meningococcal, rabies, rubella, COVID-19, varicella, and Japanese encephalitis. Available company and pipeline sources indicate a technology base centered on multivalent, combination, recombinant, inactivated, polysaccharide, and subunit vaccine approaches. Zhongyianke appears to operate primarily from Tianjin with additional R&D presence in Beijing, and it has raised venture financing from Chinese investors including Med-Fine Capital and EFung Capital. The company is best characterized as an infectious-disease vaccine developer with some commercial revenue potential from its launched influenza vaccine plus a broader clinical and preclinical vaccine pipeline.